What were Cohance Lifesciences Ltd's latest quarterly results?
Cohance Lifesciences Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -92.9%
- Revenue Growth YoY: -26.3%
- Operating Margin: 15.9%
Cohance Lifesciences Ltd: Stock Analysis & Fundamentals
Updated this weekCohance Lifesciences Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 89.6. ROE: 7.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Cohance Lifesciences Ltd Key Facts
What's Happening
👔Promoter buying — stake up 7.4% this quarter
🌐FII stake decreased 4.2% this quarter
🏛️DII accumulation — stake up 3.9%
Key Numbers
Current Price
₹462
Market Cap
17.7K Cr
Valuation
N/AOther Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Cohance Lifesciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Cohance Lifesciences Ltd's current PE ratio?
Cohance Lifesciences Ltd's current PE ratio is 89.6x.
- Current PE: 89.6x
- Market Cap: 17.7K Cr
What is Cohance Lifesciences Ltd's price-to-book ratio?
Cohance Lifesciences Ltd's price-to-book ratio is 4.5x.
- Price-to-Book (P/B): 4.5x
- Book Value per Share: ₹102
- Current Price: ₹462
Is Cohance Lifesciences Ltd a fundamentally strong company?
Cohance Lifesciences Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 8.0%
Is Cohance Lifesciences Ltd debt free?
Cohance Lifesciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹400 Cr
What is Cohance Lifesciences Ltd's return on equity (ROE) and ROCE?
Cohance Lifesciences Ltd's return ratios over recent years
- FY2024: ROCE 19.0%
- FY2025: ROCE 15.0%
- FY2026: ROCE 8.0%
Is Cohance Lifesciences Ltd's cash flow positive?
Cohance Lifesciences Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹368 Cr
- Free Cash Flow (FCF): ₹113 Cr
- CFO/PAT Ratio: 245% (strong cash conversion)
What is Cohance Lifesciences Ltd's dividend yield?
Cohance Lifesciences Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹462
Who holds Cohance Lifesciences Ltd shares — promoters, FII, DII?
Cohance Lifesciences Ltd's shareholding pattern (Mar 2026)
- Promoters: 57.5%
- FII (Foreign): 5.6%
- DII (Domestic): 21.8%
- Public: 15.1%
Is promoter holding increasing or decreasing in Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 57.5% (Mar 2026)
- Previous Quarter: 57.5% (Dec 2025)
- Change: 0.00% (stable)
Is Cohance Lifesciences Ltd a new momentum entry or an established outperformer?
Cohance Lifesciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Cohance Lifesciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Cohance Lifesciences Ltd may be worth studying
- Cash flow is positive — CFO ₹368 Cr
What is the investment thesis for Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd investment thesis summary:
What is the future outlook for Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.